ArticleTranslational psychiatry2025
Antidepressant effects of ershiwei roudoukou pills and its active ingredient Macelignan: Multiple mechanisms involving oxidative stress, neuroinflammation and synaptic plasticity.
Article in Translational psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- MicroRNAs as Regulators of Neuroinflammation in Major Depressive Disorder.Depression and anxiety · 2025Review
- Role of the microbiota in inflammation-related related psychiatric disorders.Frontiers in immunology · 2025Review
- The role of the microbiota-gut-brain axis in schizophrenia: an immunological perspective.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder (MDD) represents a significant global health burden, with current treatments showing limited efficacy and considerable side effects. While traditional medicines offer promising alternatives, their mechanisms often remain unclear. Here we demonstrate that Ershiwei Roudoukou Pills (ERP) and its active ingredient Macelignan exhibit potent antidepressant effects through multiple interconnected pathways in a chronic unpredictable mild stress (CUMS) mouse model. Both compounds significantly improved depression-like behaviors in forced swimming, tail suspension, and open field tests. Mechanistically, ERP and Macelignan restored oxidative balance by modulating multiple markers including SOD, CAT, and MDA across serum, hippocampus, and prefrontal cortex. They effectively suppressed neuroinflammation by reducing pro-inflammatory cytokines (IL-6, TNF-α) and microglial activation while increasing anti-inflammatory markers (IL-10). Furthermore, both compounds enhanced synaptic plasticity through upregulation of synaptic proteins (PSD-95, MAP2, SYP) and activation of the BDNF-TrkB signaling pathway. Notably, ERP demonstrated differential anti-inflammatory properties compared to Macelignan, with distinct effects on different inflammatory markers, suggesting potential synergistic effects from its multiple components. These findings reveal the multi-target therapeutic potential of ERP and Macelignan in treating depression, providing new insights for developing more effective antidepressant strategies, particularly for treatment-resistant cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.